Merck Serono discontinues MS candidate in Phase II
This article was originally published in Scrip
Executive Summary
Merck Serono has discontinued Phase II studies in multiple sclerosis with the injectable B-cell activating factor inhibitor atacicept. Atacicept is licensed to the company by the Seattle-based biotech, Zymogenetics.